Ashfield Capital Partners’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.25M | Sell |
15,799
-329
| -2% | -$26.1K | 0.11% | 121 |
|
|
2022
Q2 | $1.2M | Sell |
16,128
-3,054
| -16% | -$227K | 0.09% | 126 |
|
|
2022
Q1 | $1.72M | Sell |
19,182
-2,165
| -10% | -$195K | 0.11% | 122 |
|
|
2021
Q4 | $2.39M | Sell |
21,347
-3,909
| -15% | -$438K | 0.15% | 104 |
|
|
2021
Q3 | $3.18M | Buy |
25,256
+1,275
| +5% | +$160K | 0.23% | 85 |
|
|
2021
Q2 | $3.25M | Buy |
23,981
+6,068
| +34% | +$822K | 0.23% | 85 |
|
|
2021
Q1 | $2.43M | Sell |
17,913
-935
| -5% | -$127K | 0.19% | 94 |
|
|
2020
Q4 | $2.65M | Buy |
18,848
+540
| +3% | +$76K | 0.22% | 86 |
|
|
2020
Q3 | $2.04M | Buy |
18,308
+10
| +0.1% | +$1.11K | 0.19% | 97 |
|
|
2020
Q2 | $2.05M | Sell |
18,298
-3,607
| -16% | -$404K | 0.2% | 93 |
|
|
2020
Q1 | $1.7M | Buy |
21,905
+2,715
| +14% | +$210K | 0.21% | 98 |
|
|
2019
Q4 | $1.83M | Sell |
19,190
-5,510
| -22% | -$524K | 0.18% | 106 |
|
|
2019
Q3 | $1.88M | Buy |
+24,700
| New | +$1.88M | 0.2% | 102 |
|
|
2019
Q2 | – | Sell |
-26,396
| Closed | -$2.39M | – | 85 |
|
|
2019
Q1 | $2.39M | Buy |
26,396
+4,387
| +20% | +$397K | 0.26% | 88 |
|
|
2018
Q4 | $1.58M | Sell |
22,009
-13,219
| -38% | -$948K | 0.21% | 111 |
|
|
2018
Q3 | $3.38M | Buy |
35,228
+9,705
| +38% | +$930K | 0.38% | 71 |
|
|
2018
Q2 | $2.43M | Buy |
25,523
+15,241
| +148% | +$1.45M | 0.3% | 83 |
|
|
2018
Q1 | $902K | Buy |
+10,282
| New | +$902K | 0.12% | 150 |
|